Friedreich's ataxia, mitochondrial biogenesis, and neurodegeneration
弗里德赖希共济失调、线粒体生物发生和神经变性
基本信息
- 批准号:9765713
- 负责人:
- 金额:$ 43.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelAtaxiaBiogenesisBiological AssayBiological MarkersBloodBrainCell modelCerebellumClinicClinicalClinical TrialsDefectDiseaseDoxycyclineEnzymesFibroblastsFriedreich AtaxiaFunctional disorderGenesGoalsHeartHumanInflammationInheritedIronLinkLymphocyteMethodsMitochondriaMitochondrial DNAMitochondrial ProteinsModelingMusMuscleNerve DegenerationPatient-Focused OutcomesPatientsPeripheral Blood LymphocytePharmaceutical PreparationsPhenotypeProteinsPublishingRecording of previous eventsRecoveryResidual stateSeveritiesSpinal GangliaSulfurTimeTissuesTreesWorkbrain tissueexperiencefrataxinhuman tissueinsightknock-downmouse modelneurobehavioralneurophysiologyrelating to nervous systemsmall hairpin RNA
项目摘要
Friedreich's ataxia (FA) is the most common recessive inherited ataxia, comprising about half of patients seen in
ataxia clinics. FA is caused by the deficiency of a single mitochondrially-localized protein, frataxin, to about 10%
residual, and the neuropathophysiological and cardiological consequences of this mitochondrial protein depletion
are ultimately lethal. We have recently demonstrated for the first time that there is a mitochondrial biogenesis
defect proportional to the frataxin defect in FA patient fibroblasts and blood lymphocytes of living FA patients, and
decreased in multiple neural and muscle tissues in FA mouse models. This depletion of mitochondrial biogenesis
and function could turn out to be a major driver of FA pathophysiology and neurodegeneration, i.e. our premise is
that frataxin decline→mitobiogenic decline→FA neuropathophysiology and neurodegeneration. Furthermore,
because the mitobiogenesis defect occurs in blood lymphocytes of living FA patients in proportion to their frataxin
deficiency, it could provide an important blood biomarker of disease pathophysiology and/or patient outcome for
clinical drug trials. Thus we propose to investigate the contribution of the mitobiogenic defect to the ataxic
pathomechanism in the best mouse model of FA, the FXNKD mouse (Aim 1), the mechanism by which frataxin
decrease leads to the mitobiogenic defect (Aim 2), and the relevance and stability of the mitobiogenic defect in
peripheral blood lymphocytes of living FA patients, and also mitobiogenic defects in autoptic FA human target
tissues that experience neurodegeneration and cardiodegeneration (Aim 3). These studies will clarify the
pathomechanistic contribution of the frataxin-dependent defect in mitochondrial biogenesis we identified to the
ataxia in the best available mouse model of FA, and its value as a biomarker, and its relationship to the
pathomechanism in the human condition.
弗里德赖希共济失调症(FA)是最常见的隐性遗传性共济失调症,在美国约占一半
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gino A Cortopassi其他文献
Méthodes de traitement de maladies mitochondriales
疾病线粒体性状测定方法
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
Gino A Cortopassi;Sandip K. Datta;Alfred Yu - 通讯作者:
Alfred Yu
Gino A Cortopassi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gino A Cortopassi', 18)}}的其他基金
Mitochondrial-mediated Lung Injury mechanisms of QACs in vivo
QACs 体内线粒体介导的肺损伤机制
- 批准号:
10675747 - 财政年份:2022
- 资助金额:
$ 43.16万 - 项目类别:
Mitochondrial-mediated Lung Injury mechanisms of QACs in vivo
QACs 体内线粒体介导的肺损伤机制
- 批准号:
10467271 - 财政年份:2022
- 资助金额:
$ 43.16万 - 项目类别:
'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics
“新型 Shc 阻滞剂作为潜在的阿尔茨海默病治疗药物
- 批准号:
10395302 - 财政年份:2021
- 资助金额:
$ 43.16万 - 项目类别:
'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics
“新型 Shc 阻滞剂作为潜在的阿尔茨海默病治疗药物
- 批准号:
10611613 - 财政年份:2021
- 资助金额:
$ 43.16万 - 项目类别:
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
研究酮症治疗的靶标、机制和最佳给药方式,以实现功能性长寿和阿尔茨海默氏病的治疗
- 批准号:
10203670 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Targeting Shc to reduce inflammation and fibrosis in the aging liver
以 Shc 为靶点,减少衰老肝脏的炎症和纤维化
- 批准号:
10436913 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism
阐明生酮长寿机制的生物标志物和机制
- 批准号:
10398862 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism
阐明生酮长寿机制的生物标志物和机制
- 批准号:
10685456 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
研究酮症治疗的靶标、机制和最佳给药方式,以实现功能性长寿和阿尔茨海默氏病的治疗
- 批准号:
10685449 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
研究酮症治疗的靶标、机制和最佳给药方式,以实现功能性长寿和阿尔茨海默氏病的治疗
- 批准号:
10153620 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 43.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




